Priorities for improvement in health in patients with rheumatoid arthritis (RA) who are starting disease-modifying antirheumatic drugs (DMARDs), including biological agents

被引：0
|
作者：
Heiberg, T
Vinders, M
Olsen, CL
Magnussen, AS
Enersen, TB
Fekete, S
Kvien, TK
机构：
[1] Ullevaal Univ Hosp, Dept Adm, Oslo, Norway
[2] Lillehammer Hosp Rheumat Dis, Dept Rheumatol, Lillehammer, Norway
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] St Olav Hosp, Dept Rheumatol, Trondheim, Norway
[5] Buskerud Cent Hosp, Dept Rheumatol, Drammen, Norway
[6] Univ Hosp No Norway, Dept Rheumatol, Tromso, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [21] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [22] EFFICACY OF NON-BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN PATIENTS (PTS) WITH EXTRA-ARTICULAR RHEUMATOID ARTHRITIS (EXRA)
    Mykytenko, G.
    Iaremenko, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 894 - 894
  • [23] Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Kishimoto, Mitsumasa
    Nishijima, Nobuo
    Yamashita, Katsuhisa
    Matsushima, Junnosuke
    O'Brien, Jacqueline
    Blachley, Taylor
    Eliot, Melissa
    Margolin, Zachary
    Dave, Swapna S.
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2023, 34 (01) : 27 - 36
  • [24] Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Inose, Ryo
    Hashimoto, Natsue
    Hosomi, Kouichi
    Yokoyama, Satoshi
    Takada, Mitsutaka
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (03) : 131 - 138
  • [25] PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Schlager, Lukas
    Loiskandl, Michaela
    Aletaha, Daniel
    Radner, Helga
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1152 - 1153
  • [26] Incidence and severity of laboratory abnormalities during treatment with disease modifying antirheumatic drugs (DMARDS) in patients with rheumatoid arthritis (RA).
    Simon, CH
    Dijkmans, BAC
    Moens, HJB
    Vandenbroucke, JP
    Breedveld, FC
    Vlieland, TPMV
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S211 - S211
  • [27] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
    Di Munno, O
    Delle Sedie, A
    Rossini, A
    Adamil, S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
  • [28] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [29] Racial Differences in Productivity Loss Attributable to Rheumatoid Arthritis Among Patients Taking Disease-Modifying Antirheumatic Drugs (DMARDs)
    Bozzi, Laura M.
    Gaitonde, Priyanka
    Shaya, Fadia
    Tom, Sarah E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 618 - 618
  • [30] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN THE TREATMENT OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    HALBERG, P
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1986, : 55 - 57
12345